Receptor tyrosine kinases of the Eph family are upregulated in several different types of cancer. One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma. However, mechanisms by which EphA2 contributes to tumor progression are far from clear. In certain tumor cell lines, EphA2 receptor is underphosphorylated, raising the question of whether ligandinduced receptor phosphorylation and its kinase activity play a role in oncogenesis. To test directly the role of EphA2 receptor phosphorylation/kinase activity in tumor progression, we generated EphA2 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its kinase activity. Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor volume and increased tumor apoptosis in primary tumors. In addition, the numbers of lung metastases were significantly reduced in both experimental and spontaneous metastasis models. Reduced tumor volume and metastasis are not due to defects in tumor angiogenesis, as there is no significant difference in tumor vessel density between wild-type tumors and tumors expressing EphA2-signaling-defective mutants. In contrast, tumor cells expressing the EphA2 mutants are defective in RhoA GTPase activation and cell migration. Taken together, these results suggest that receptor phosphorylation and kinase activity of the EphA2 receptor, at least in part, contribute to tumor malignancy.
Introduction
Receptor tyrosine kinases (RTKs) play a diverse role in cell growth and differentiation during normal physiologic responses and in oncogenic transformation and tumor progression. These cell surface receptors transmit extracellular signals by activation of intrinsic kinase activity, which phosphorylates cytoplasmic domains of clustered receptor complexes and other target proteins, thus initiating a cascade of signaling events that modulate cellular responses. Mutations leading to production of constitutively active receptors or overexpression of a normal receptor results in increased kinase activity and oncogenic transformation. Consequently, small molecule inhibitors of receptor tyrosine kinases are proving to be efficacious in the clinic for several cancer types (reviewed in Madhusudan and Ganesan, 2004) .
Eph receptors represent the largest family of receptor tyrosine kinases in the genome, consisting at least 16 receptors that interact with nine membrane-bound ephrin ligands (reviewed in Brantley-Sieders and Chen, 2004; Pasquale, 2005) . They can be further divided into two groups, class A and B, based on sequence homology and binding affinity (Gale et al., 1996) . Class A Eph receptors interact with multiple ligands of the ephrin-A family, a group of glycosyl-phosphoatidylinositol (GPI)-linked membrane proteins, while class B Eph receptors binds to ephrin-B ligands, a family of transmembrane proteins. Binding of Eph receptors to their ligands induces receptor clustering, activation of kinase activity, and subsequent trans-phosphorylation of the cytoplasmic domains, creating docking sites for a number of signaling proteins (reviewed in Kullander and Klein, 2002; . In addition to kinasedependent signaling, binding of certain members of the Eph family, such as EphA8 or EphB3, can also trigger kinase-independent signaling (Gu and Park, 2001; Miao et al., 2004) . In contrast to other families of receptor tyrosine kinases, Eph receptor signaling does not promote proliferation but leads to regulation of cellcell, cell-matrix adhesion and cell motility.
The Eph family RTKs and their ligands initially attracted interest as modulators of axonal guidance, angiogenesis, and embryonic patterning during development (reviewed in Holder and Klein, 1999; Kullander and Klein, 2002) . It is now clear that the Eph molecules also play a role in adult tissues under physiological conditions and in disease states such as cancer. Eph RTKs and their ligands, the ephrins, are frequently overexpressed in different types of cancer (reviewed in Nakamoto and Bergmann, 2002; Brantley-Sieders et al., 2004b; Ireton and Chen, 2005) . One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma (Ogawa et al., 2000; Walker-Daniels et al., 2003) . In cell lines, EphA2 overexpression is associated with increased cell growth in soft agar (Zelinski et al., 2001) , increased invasion into matrigel (Zelinski et al., 2001; Duxbury et al., 2004a) , increased resistance to anoikis (Duxbury et al., 2004a) , and increased tumor growth when these cells were implanted into nude mice (Zelinski et al., 2001) . Conversely, inhibition of EphA2 expression in tumor cells by siRNA (Duxbury et al., 2004a) or induction of EphA2 degradation by ligand-or activating antibody-induced endocytosis (WalkerDaniels et al., 2002) resulted in decreased cell invasion into matrigel, increased anoikis, and inhibition of tumor growth in vivo (Carles- Duxbury et al., 2004b) . However, despite the strong correlation of EphA2 receptor expression with malignant phenotypes, the mechanisms by which EphA2 contributes to tumor cell malignancy are far from clear.
One important mechanistic question is whether EphA2 receptor phosphorylation and kinase activity play a role in malignant transformation/progression. In certain tumor cell lines, EphA2 receptor is underphosphorylated (Zantek et al., 1999) . However, despite the low phosphorylation level, EphA2 kinase activity was not affected (Zantek et al., 1999) . Ligand-induced EphA2 phosphorylation induces receptor endocytosis and degradation, reducing malignant behavior of the cells and tumor growth in vivo (Walker-Daniels et al., 2002) . Such evidence supports the idea that EphA2 receptor phosphorylation is not necessary to confer kinase activity and tumorigenicity, but leaves question unanswered as to whether kinase activity is required for tumor malignancy. Other data have emerged showing that EphA2 receptor phosphorylation may be important in conferring oncogenic potential. Dobrzanski et al. (2004) observed high EphA2 receptor phosphorylation levels in xenografts of ASPC-1, U87MG, and SVP cell lines. Ogawa also reported EphA2 receptor phosphorylation in human mammary carcinoma xenography (Ogawa et al., 2000) . In addition, studies using the 4T1 model of tumorigenesis have found that blocking EphA2 receptor activation through EphA2-Fc results in a decrease in phosphorylation that was concurrent with decreased tumor volume Cheng et al., 2003; Dobrzanski et al., 2004) .
To directly test the role of EphA2 receptor phosphorylation/kinase activity, we overexpressed EphA2 variants, either lacking the cytoplasmic domain or carrying a point mutation that abolishes its kinase activity, in breast cancer cells. Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor volume and increased tumor apoptosis in primary tumors, and significantly reduced the number of lung metastases. These data suggest that phosphorylation and kinase activity of the EphA2 receptor, at least in part, contributes to tumor malignancy.
Results

EphA2 receptor phosphorylation in tumor cells is regulated by cell density
Prior studies have shown that EphA2 receptors are underphosphorylated in certain breast tumor cell lines (Zantek et al., 1999) but phosphorylated in other tumor cells (Dobrzanski et al., 2004) . As 4T1 tumor cells express both endogenous ephrin-A1 ligand and EphA2 receptor , we determined whether EphA2 receptors are tyrosine phosphorylated by engaging endogenous ephrin-As in a cell-cell contactdependent manner, and whether the level of EphA2 tyrosine phosphorylation can be further elevated by exogenous ephrin-A1 ligand. We used two independent approaches to address this issue. First, cells were plated onto 10-cm dishes with 100, 50, or 25% confluency in the presence or absence of 1 mg/ml exogenous ephrin-A1 ligand for 15 min. Cell lysates were immunoprecipitated by anti-EphA2 and blotted for phosphotyrosine level. As shown in Figure 1a , phosphorylation of EphA2 receptor is upregulated with increased cell density at basal level, and phosphorylation of EphA2 is further enhanced by exogenous ephrin-A1 ligand stimulation. In a second approach, identical numbers of 4T1 tumor cells were plated on culture dishes of different surface areas (3.5, 6, and 10 cm) so that cell density decreases with the increase of dish size (Figure 1b) . In cells on 10 cm dish where there is no significant level of cell-cell contact, EphA2 is barely activated in the absence of ligands, yet became tyrosine phosphorylated upon exposure to exogenous ephrin-A1. With increasing cell density (6 and 3.5 cm), EphA2 receptor expression level gradually decreases. However, when adjusted to similar level of EphA2 expression by combining cells in five dishes of 3.5 cm plate, the EphA2 tyrosine phosphorylation level increases in high-density cell culture (Figure 1b , lanes labeled as 3.5 cm). Ephrin-A1 levels did not change significantly with different cell density (Figure 1c) . These results revealed that high cell density upregulates basal level of tyrosine phosphorylation of EphA2 receptor and phosphorylation of EphA2 receptor can be further increased by stimulation of exogenous ephrin-A1 ligand.
Signaling-defective forms of EphA2 mutants inhibit 4T1 mammary tumor progression in vivo
To test directly the role of EphA2 receptor phosphorylation/kinase activity, we generated EphA2 mutants that were either lacking the cytoplasmic domain (DC) or carrying a D738N point mutation (W42) (Figure 2a ). W42 mutation is analogous to a spontaneously occuring loss of function point mutation identified in the W 42 dominant-negative allele of the c-kit receptor tyrosine kinase (Reith et al., 1990 (Reith et al., , 1991 ) that serves as a dominant-negative mutation for other RTKs in cell culture models (Reith et al., 1993) . EphA2-deficient cells were infected with LZRS retrovirus expressing wild-type EphA2 receptor (WT), W42 mutant, or vector control and kinase activity of each receptor variant was determined by in vitro kinase assay. As shown in Figure 2b , EphA2-deficient cells have no detectable level of kinase activity. While overexpression of WT restored kinase activity, overexpression of W42-mutant protein failed to confer kinase activity in EphA2-deficient cells, suggesting that W42 is a kinase-dead mutant.
Multiple 4T1 clones expressing either WT, signalingdefective mutant forms of EphA2, DC or W42, or control vector were generated. As shown in Figure 2c , compared to vector control, overexpression of wild-type EphA2 leads to a constitutive phosphorylation of the receptor. In contrast, overexpression of mutant DC or W42 forms of EphA2 significantly inhibited ligandinduced receptor phosphorylation, suggesting that these mutants act in a dominant negative fashion to inhibit endogenous receptor signaling. As expected, transfected wild-type or mutant EphA2 proteins localized to the cell surface of culture cells (data not shown). When cultured in vitro, there are no significant changes in either cell proliferation or apoptosis among multiple 4T1 clones expressing wild-type or signaling-defective mutant forms of EphA2 receptor ( Figure 2d ).
To assess whether EphA2 function in tumor growth and metastasis is kinase dependent, 4T1 clones expressing either wild-type or mutant EphA2 proteins (100 000 cells) were injected in the mammary fat pad of syngeneic Balb/C-recipient mice, and tumors were harvested 1 week later for analysis. While tumors expressing wild-type EphA2 have similar tumor volume as control tumors, tumors expressing either DC or W42 mutants ) of 4T1 cells were plated on culture dishes of different surface areas (3.5, 6, and 10 cm dish). Cells were serum-starved overnight and stimulated with 1 mg/ml of ephrin-A1 ligand for 15 min. EphA2 proteins were immunoprecipitated from cell lysates and blotted for tyrosine phosphorylation and for total EphA2. Relative levels of pEphA2 and total EphA2 were quantified by densitometry using Scion image 1.62 software analysis. Five dishes of 3.5 cm plate were pooled for Western blot analysis. (c) Western blot analysis of ephrin-A1 ligand ( Figure 3a ) have a much smaller tumor volume (Po0.01, ANOVA; Po0.01, unpaired Student's t-test, DC-1, DC-2, or W42 versus Vector, WT-1 or WT-2). We next determined whether decreased tumor volume in tumors expressing EphA2 signaling-defective mutants is due to decreased proliferation or increased apoptosis. Tumor growth was assessed by quantifying nuclear expression of proliferating cell nuclear antigen (PCNA), a marker for actively dividing cells; and cell death was determined by in situ TUNEL stain in tumor sections. As shown in Figure 3b , compared to wild-type EphA2 tumors, there is an approximately two-fold increase in TUNEL-positive nuclei in tumors expressing signalingdefective EphA2 mutants (Po0.01, ANOVA; Po0.01 Student's t-test. Vector or WT versus DC-1, DC-2, or W42). However, there is no significant difference in tumor cell proliferation between tumors expressing wildtype EphA2 and those expressing EphA2 mutants (data not shown), consistent with studies suggesting that Eph RTKs do not promote proliferation directly . Taken together, these data suggest that blockade of EphA2 forward signaling in tumor cells EphA2-deficient endothelial cells were infected with retrovirus LZRS-expressing wild-type EphA2, W42 mutant, or vector control. Cells were serum-starved overnight and stimulated with 1 mg/ml of ephrin-A1 ligand for 15 min. EphA2 proteins were immunoprecipitated and subjected to in vitro kinase assay. W42 mutant is defective in kinase activity. (c) 4T1 clones expressing wild-type and mutant forms of EphA2 receptors were subject to immunoprecipitation/Western blot analysis for EphA2 and phosphorylated tyrosine as in Figure 1 . EphA2-DC and W42 mutants act in a dominant-negative fashion to inhibit endogenous EphA2 receptor phosphorylation in response to ephrin-A1 ligand. (d) In vitro analyses of proliferation and apoptosis in 4T1 cells expressing wild-type or mutant forms of EphA2. Cell proliferation and apoptosis were assessed by expression of proliferating cell nuclear antigen (PCNA) and activated caspase-3, respectively. There is no significant difference in proliferation or apoptosis between 4T1 expression wild-type or mutant EphA2 proteins by signaling-defective EphA2 mutants inhibits tumor progression by promoting tumor cell apoptosis.
Signaling-defective forms of EphA2 mutants inhibit lung metastasis
To determine whether blocking of EphA2 signaling in tumor cells could suppress metastatic progression, 10 000 4T1 cells expressing either wild-type or mutant forms of EphA2 proteins were administered intravenously into Balb/C-recipient mice. At 12 days after injection, lungs were harvested, fixed, and processed for histological analyses. Gross examination revealed numerous lung surface metastases in mice injected with 4T1 cells expressing wild-type EphA2, compared to 4T1 cells containing vector alone (Figure 4a , top panels). In contrast, there were significantly lower numbers of visible lung surface metastases in mice injected with 4T1 cells expressing signaling-defective EphA2 mutants (Figure 4a , bottom panels), compared to 4T1 cells expressing wild-type EphA2. Histological examination of hematoxylin/eosin-stained lung sections revealed numerous large pulmonary metastases in lungs from mice harboring wild-type EphA2 tumors, while only small avascular metastases could be seen in lungs from mice harboring either DC-EphA2 or W42-EphA2 tumors (data not shown). Comparison of tumor metastasis by counting the lung surface metastases confirmed that mice injected with 4T1/WT-EphA2 cells carried a significantly greater metastatic burden than mice injected with cells expressing either vector control, (Figure 4b ) (Po0.01, ANOVA; Po0.05, unpaired Student's t-test, DC-1, DC-2, or W42 versus WT-1 or WT-2). These results suggest that signalingdefective forms of EphA2 mutants inhibit the colonization of tumor cells in the lung.
To determine whether signaling-defective forms of EphA2 mutants could also inhibit spontaneous metastases, 500 000 parental 4T1 cells or 4T1 cells expressing wild-type or mutant EphA2 receptors were implanted into mammary gland fat pads of recipient Balb/C females and tumors were grown for 21 days to permit spontaneous lung metastases. Consistent with data derived from 1-week tumors, we observed significantly decreased tumor volume in tumors expressing DC or W42 at 3 week (Figure 5a ) (Po0.01, ANOVA; Po0.01, unpaired Student's t-test, DC-1, or W42 versus 4T1 or WT-1). The number of surface lung lesions in EphA2 signaling-defective tumor recipients was also reduced compared to controls (data not shown). Quantification of total lesions in cleared lungs by staining with hematoxylin revealed a significant decrease in tumor expressing EphA2 mutants relative to controls (Figure 5b ) (Po0.01, ANOVA; Po0.01, unpaired Student's t-test, DC-1, or W42 versus WT-1). These data demonstrate that EphA2 signaling-defective mutants inhibit tumor metastasis in vivo.
Signaling-defective EphA2 mutants do not affect tumor angiogenesis but inhibit tumor cell motility
It has become increasing clear that multiple factors could influence tumor metastasis, including tumor angiogenesis and increased tumor cell motility. As EphA2 receptor and ephrin-A ligands were previously shown to be involved in tumor neovascularization Cheng et al., 2003; Dobrzanski et al., 2004) , we first determined the abundance of microvessels in tumors expressing either wild-type or mutant EphA2 receptors. No significant difference of tumor microvascular density was observed between tumors expressing wild-type and mutant EphA2 receptors (data not shown), suggesting that tumor angiogenesis is not a determining factor for decreased tumor metastasis in tumors expressing mutant EphA2 receptors.
Next, we determined the ability of cells to migrate, as cell motility contributes to tumor invasion and metastasis. 4T1 cells expressing WT, W42, DC, or vector control were grown to confluency and monolayer of cells was then scratched with a pipette tip. As shown in Figure 6a , the wound closing process was significantly retarded in 4T1 cells expressing mutant W42 or DC receptor, compared to those expressing WT receptor, vector control, or parental 4T1 cells, suggesting that blocking of EphA2 receptor signaling inhibits tumor cell motility. As dynamic regulation of the actin cytoskeleton is critical in cell migration and Rho family GTPases are known to be key regulators of this process (reviewed in Ridley, 2001; Fukata et al., 2003; Malliri and Collard, 2003) , we examined the level of activated Rho family GTPases in 4T1 clones expressing wild-type or mutant EphA2 by GST-Rhotekin or GST-PAK pull-down assays. As shown in Figure 6b , there is no significant difference in Rac activity between cells expressing wildtype EphA2 and those expressing mutant EphA2 proteins, although Rac activity appears to increase in cells expressing EphA2 proteins for unknown reasons. In contrast, ephrin-A1 stimulation induced RhoA activation within 2.5 min in both vector-transfected 4T1 cells and 4T1 cells expressing WT-EphA2. RhoA activation was undetectable in cells expressing W42-EphA2 or DC-EphA2-mutant proteins. Thus, it appears that the changes in RhoA activity is more relevant to phenotypes we observed. Taken together, these data suggest W42-EphA2 or DC-EphA2 mutants may suppress tumor cell migration through inhibition of RhoA activation.
Discussion
Classic oncogenic transformation by receptor tyrosine kinases and their growth factor ligands involves elevated levels of receptor autophosphorylation and tyrosine kinase activity. In fact, an abnormally high level of tyrosine kinase activity is the major determinant of the oncogenic potential of a RTK, as is the case for ErbB2/ Neu (Segatto et al., 1988) . However, it is not clear Figure 5 EphA2-DC or W42 mutants inhibit spontaneous lung metastasis. In all, 500 000 tumor cells were orthotopically implanted into mammary gland of syngeneic recipient Balb/C female mice. Primary breast tumors and lungs were collected 21 days later. (a) Tumors expressing DC or W42 mutants exhibit significantly smaller tumor volume than those of 4T1 parental or wild-type control tumors. (b) Quantification of total lung metastases revealed a significant decrease in lung lesions from mice harboring tumors expressing DC or W42 mutants relative to controls whether receptor autophosphorylation and kinase activity is required for EphA2 receptor-mediated oncogenic transformation or in the development of metastatic potential. siRNA knock down of EphA2 receptor tyrosine kinase expression in pancreatic cancer cells inhibits tumor growth and metastasis (Duxbury et al., 2004a) , but this study did not address whether the kinase activity is required for tumor malignancy. Soluble EphA2-Fc receptor can effectively inhibit EphA2 receptor phosphorylation and tumor growth and metastasis in vivo Cheng et al., 2003; Dobrzanski et al., 2004) . While this study supported the notion that EphA2 receptor phosphorylation/activation is required for tumor progression, these in vivo studies cannot differentiate the effect of soluble EphA2-Fc receptor on tumor cells from other cell types in the tumor microenvironment. Finally, Zantek et al. (1999) showed that EphA2 receptor is not phosphorylated in some human breast cancer cell lines, although the unphosphorylated receptor still has kinase activity. Overexpression of EphA2 receptor in the immortalized breast epithelial cell line MCF10A induces oncogenic transformation, but again the overexpressed EphA2 receptor is not phosphorylated (Zelinski et al., 2001) . These data argue for a phosphorylation-independent role of EphA2 in oncogenic transformation. In this report, we found that EphA2 level and phosphorylation status are cell density dependent in culture. Inhibition of receptor phosphorylation by EphA2 mutants that either contain a cytoplasmic deletion (DC) or a point mutation rendering 'kinase-dead' (W42) suppressed the activity of RhoA GTPase and tumor cell motility. Furthermore, blocking of EphA2 receptor signaling by DC or W42 mutants inhibited tumor growth and lung metastasis in vivo. Taken together, our results suggest a kinase-dependent role of EphA2 in tumor progression.
In addition to a kinase-dependent role of EphA2 in tumor progression, EphA2 may also have kinaseindependent functions. Genetic studies in vivo have shown that Eph receptors have both kinase-dependent and -independent functions (Birgbauer et al., 2000; Dalva et al., 2000; Grunwald et al., 2001; Kullander et al., 2001 ). In addition, some Eph receptors either have kinase-deficient variant forms generated by alternative splicing (EphA6, 7, and B1) (Zisch and Pasquale, 1997) or have kinase domains with defective catalytic activity (EphB6 and A10) (Gurniak and Berg, 1996; Manning et al., 2002) . Activation of EphA8 induce extracellular matrix adhesion through a PI3Kg-mediated regulation of integrin activity in a kinase-independent manner (Gu and Park, 2001 ). More recently, Miao et al. (2004) showed that inhibition of integrin-mediated cell adhesion but not directional cell migration requires EphB3 tyrosine kinase activity (Miao et al., 2004) . Finally, the phenotypes of DC tumors are more severe than W42 tumors, suggesting an additional function of cytoplasmic domain of EphA2 receptor independent of its kinase activity.
Aside from EphA2 receptor, the expression of EphB4 receptor is also elevated in breast carcinomas with a Figure 6 Reduced cell migration in 4T1 cells expressing DC or W42 EphA2 mutants. Cells were cultured in 12-well plates until confluency. The monolayer was wounded with a fine pipette tip to create a circular wound. (a) Pictures were taken at 2, 4, 6, 8, and 24 h after wounding. Residual 'wound' areas were measured and quantified by Scion Image software. Percentage of remaining wounded area in 4T1 cells expressing DC or W42 EphA2 mutants at 24 h is significantly greater than controls, indicating reduced migration. (b) Active GTP-bound forms of RhoA and Rac1 were analyzed by Rhotekin-RBD or Pak-PBD pull-down followed by immunoblot in lysates from 4T1 cells overexpressing wild-type or mutant forms of EphA2 receptors or vector control. Expression of DC or W42 EphA2 mutants blocked basal and ephrin-A1-induced RhoA activation but had no significant effect on Rac1 activation high grade of malignancy (Berclaz et al., 1996) . In transgenic mouse models of mammary carcinogenesis, overexpression of EphB4 in mammary epithelial cells leads to accelerated tumor growth and metastatic progression caused by the Neu oncogene (Munarini et al., 2002) . Interestingly, tumor promotion effects of the EphB4 overexpression may not be due exclusively to EphB4 forward signaling, as overexpression of a EphB4 cytoplasmic trunction mutant, EphB4DC-EGFP, also increases tumor growth . The tumor growth promotion effects of EphB4DC-EGFP are apparently due to reverse signaling through ephrin-B2 via enhanced tumor angiogenesis . Although there is precedence for reverse signaling through class A ephrin ligands (Davy et al., 1999; Davy and Robbins, 2000; Huai and Drescher, 2001 ), we do not think the tumor suppression effect of DC-EphA2 or W42-EphA2 is due to reverse signaling because WTEphA2 retains the capability to signal through ephrinAs but have the opposite biologic outcome. As both WT-EphA2 and signaling-defective EphA2 mutants are specifically expressed in the tumor cells, we believe the reduced tumor volume and decreased metastasis in DCEphA2 or W42-EphA2 tumors is due to defective forward signaling in tumor cells.
What is the mechanism of EphA2 signaling-defective mutant-mediated inhibition of tumor progression in vivo? Inhibition of primary tumor growth could result from suppression of tumor cell proliferation or enhancement of tumor cell death directly, or reduction of tumor blood vessels indirectly. As we did not observe any changes in tumor cell proliferation or tumor vessel density, increased apoptosis is likely to play a major role in diminishing tumor volume in primary tumors expressing EphA2 signaling-defective mutant proteins. It is interesting to note that while program cell death is increased in tumors expressing signaling mutant forms of EphA2 receptor (Figure 3b ), we did not observe a significant change between wild-type and mutant forms of EphA2 in apoptosis in cultured cells under serum starvation in vitro (Figure 2d ). As tumor in vivo interacts with its complex microenvironment, apoptosis can occur in response to stimuli (e.g. Fas ligand) other than cytokine/nutrient deprivation. Further experiments will be needed to dissect the role of EphA2 receptor in cell survival in vivo.
Tumor metastasis is a complex multistep process involving tumor cell invasion, intravasation, survival in the circulation, extravasation, local migration, and colonization of secondary organs. Decreased cell motility and increased apoptosis in tumors expressing EphA2 signaling-defective mutant proteins could affect multiple steps of the metastatic process, leading to decreased metastatic lesions in vivo. Comparison of the results from experimental metastasis with those from spontaneous metastasis suggests that in addition to a possible role in tumor cell invasion and intravasation, EphA2 receptor is also essential in later steps of metastasis involving colonization of lung tissue. In addition to the effect of EphA2 signaling on metastasis, recent data from multiple laboratories showed that the level of EphA2 expression correlates with the degree of tumor malignancy and metastasis Miyazaki et al., 2003; Saito et al., 2004) , suggesting high level of EphA2 protein promotes metastasis. In support of this hypothesis, we observed that mice received 4T1 expressing wild-type EphA2 exhibited elevated number of lung metastases compared to those receiving parental 4T1 cells or 4T1 vector controls (Figures 4b and 5b) . Although there is no significant difference in cell migration between WT-1 and parental 4T1 cells, it is conceivable that WT-1 has advantage over parental 4T1 in other steps of metastasis. For example, EphA2 has been shown to regulate the expression of MMP-2 (Duxbury et al., 2004b) . Thus, in principle, one mechanism by which elevated EphA2 receptor could promote tumor cell invasion and colonization is via an MMP-dependent mechanism.
Cell migration can be divided into separate steps: lamellipodium extension, formation of new adhesions, cell body contraction and tail detachment. Rho family small GTPases are well established as mediators in these steps: Rac 1 is required for lamellipodium extension and formation of new adhesion, while RhoA is primarily involved in stress fiber formation and cell body contraction (reviewed in Ridley, 2001 ). In general, Rac1 activation promotes cell migration. However, RhoA activation can either inhibit or promote cell migration depending on cell types and experimental conditions (Ridley, 2001) . In less adherent cells such as macrophages, neutrophils, and various cancer cell lines, RhoA activity has been correlated to cell polarization and migration (Wicki and Niggli, 2001 ). Under our experimental condition, we did not observe a significant decrease in Rac1 activity. Rather, a dramatic inhibition of RhoA activity is seen in tumor cells expressing EphA2 signaling-defective mutants. As 4T1 cells are very malignant metastatic cancer cells, activation of RhoA in this cell type may resemble to that of nonadherent cells to promote cell migration. This hypothesis is consistent with the fact that elevated expression of RhoA has been correlated with advanced tumor stage or enhanced metastasis in tumors, including breast cancer, melanomas, pancreatic ductal adenocarcinoma and testicular germ cell tumors (Lozano et al., 2003) .
Since EphA2 receptor is frequently overexpressed in human cancers and the level of EphA2 expression has been correlated with tumor malignancy, therapeutic strategies are currently being developed to inhibit EphA2 in cancer. These includes downregulation of EphA2 expression by siRNA (Duxbury et al., 2004a) , activating antibodies or ligand mimetic peptides to induce EphA2 endocytosis and degradation (Koolpe et al., 2002; Coffman et al., 2003) , or blocking EphA2 receptor activation by soluble EphA-Fc receptor Cheng et al., 2003; Dobrzanski et al., 2004) . This study provides a mechanism for effectiveness of soluble EphAFc receptor and lays foundation for future development of EphA2-specific kinase inhibitors in cancer therapeutics.
Materials and methods
Plasmids, antibodies, and reagents
The dominant-negative EphA2 receptor mutant, W42-EphA2, carries a D738N point mutation that is analogous to that identified in the spontaneously occurring dominant-negative W42 mutant allele of c-kit (Reith et al., 1990) . Mutation of this conserved residue has previously been shown to confer dominant-negative signaling properties in c-Kit and other RTKs in cell-based assays (Reith et al., 1991 (Reith et al., , 1993 . The myctagged-dominant negative EphA2 cytoplasmic domain truncation mutant (EphA2-DC) was generated by PCR amplification of the extracellular and transmembrane domain of EphA2 and subcloned into pcDNA 3.1 (Invitrogen). Antibodies used for immunoblot include: anti-myc (1 : 500; Cell Signaling Technology), anti-EphA2 (1 : 500), anti-ephrin-A1 (1 : 500) and phosphotyrosine antibodies (1 : 250; Santa Cruz Biotechnology), anticleaved caspase-3 (1 : 100, Cell signaling), anti-PCNA (0.5 mg/ml, Neomarkers), anti-tubulin (1 : 1000; SigmaAldrich), anti-Rac1 (Pharmingen, 1 : 250) and anti-RhoA (Santa Cruz, 1 : 250) antibodies. A mixture of polyclonal antiEphA2 (0.5 mg; C-20, Santa Cruz Biotechnology) and monoclonal anti-EphA2 (1 mg; D7, Upstate Biotechnology) antibodies were used to immunoprecipitate EphA2 from 4T1 cell lysates. Recombinant ephrin-A1-Fc proteins were purchased from R&D systems (Minneapolis, MN, USA).
Immunoprecipitation, Western blot analysis, and kinase assay EphA2 immunoprecipitation was described previously . For Rac1 and RhoA activation assays, 4T1 or 4T1 transfectants were serum starved for 24 h in serum-free Optimum medium followed by stimulation with ephrin-A1 (1 mg/ml). Lysates were prepared and incubated with Pak-1-binding domain (PBD)-GST beads or Rhotekin-binding domain (RBD)-GST beads as described previously (BrantleySieders et al., 2004a) . Activated Rac1 and RhoA (or total Rac1 and RhoA in lysates) were detected by immunoblot using antiRac1 or anti-RhoA antibodies.
For kinase assay, wild-type and EphA2-deficient lung microvascular endothelial cells were isolated from EphA2 knockout mice (Brantley-Sieders et al., 2004a) and were infected with LZRS retrovirus expressing wild-type or W42 mutant form of EphA2 receptor. Parental and infected cells were serum starved for 24 h in serum-free Optimum medium followed by stimulation with ephrin-A1 (1 mg/ml). Cells were lysed and EphA2 were immunoprecipitated with an antiEphA2 antibody (2 mg, C-20, Santa Cruz) in Triton X-100 buffer (20 mM Tris-Cl, 150 mM NaCl, 25 mM b-glycerophosphate, 2 mM EDTA, 10% glycerol,1% Triton X-1000, 1 mM DTT, 1 mM sodium orthovanadate, 10 mg/ml Leupeptin, and 1 mM PMSF). The samples were resuspended in 25 ml kinase buffer [20 mM HEPES pH ¼ 7.6, 20 mM b-glycerophosphate, 0.1 mM sodium orthovanadate, 10 mM MgCl2, 50 mM NaCl, 1 mM DTT, 200 mM ATP, and 20 mCi [g-32 P] ATP (NEN, NEG502A500UC)], incubated at 301C for 25 mins, resolved on a 8% SDS-polyacrylamide gel, and transferred to nylon membrane for autoradiography. The blot was stripped and re-probed with anti-EphA2 to ensure equal loading.
Orthotopic tumor transplantation
BALB/c mice, 10 weeks of age, were injected with 1 Â 10 5 4T1 cells in the left inguinal mammary gland. The primary tumors were harvested 1 week after injection. Tumor size was assessed by caliper measurements, and the tumor volume was calculated by the following formula: Tumor volume ¼ 0.52 Â width 2 Â length (Bergers et al., 1999) . BALB/c female animals (10 weeks old) were obtained from Harlan Sprague-Dawley and housed under pathogen-free conditions. All experiments were performed in accordance with AAALAC guidelines and with Vanderbilt University Institutional Animal Care and Use Committee approval.
Histologic analyses
Tumors isolated from BALB/c female mice were processed for histology by overnight fixation in 10% neutral-buffered formalin (Fisher Scientific) at 41C followed by paraffin embedding and preparation of 7 mm sections. Apoptosis was assessed by TUNEL assay using an Apotag red in situ apoptosis detection kit (Serologicals Corporation, Norcross, GA, USA) as described previously . Images were captured using an Olympus BX60 microscope and digital camera. The percentage of apoptotic nuclei was calculated based on the number of TUNEL þ nuclei divided by the number of DAPI þ nuclei (total nuclei) in four random 20 Â fields/section. Proliferation was assessed by quantification of PCNA-positive nuclei as described previously ; data not shown).
Metastasis assay
For the experimental metastasis studies, BALB/c mice were administered with 1 Â 10 4 4T1 cells intravenously. The lungs were harvested 12 days after injection. The lungs were fixed by intratracheal infusion of 10% neutral formalin and embedded as described above for primary tumors. Surface lung metastases were scored in a blind fashion under the dissecting microscope. For spontaneous metastasis studies, 10-week-old BALB/c females were injected with 5 Â 10 5 4T1 cells in the left inguinal mammary gland as described (Yang et al., 2004) . The primary tumors and lungs were harvested after 21 days. Lungs were fixed for 24 h in 10% neutral-buffered formalin at 41C, dehydrated, and cleared by washing three times, 1 h each, in xylenes (Fisher Scientific). Lungs were rehydrated and stained in Mayer's hematoxylin (Sigma-Aldrich) for 1 h at room temperature. After briefly washing in tap water, lungs were destained in 15-min washes with 1% v/v HCl, dehydrated and cleared in xylenes. The lungs were then equilibrated into methyl salicylate (Sigma) for enumeration of metastases.
Wound closure assay
The wound closure assay was described previously . Briefly, the 4T1 cells were grown to confluence in six-well tissue culture plates. Replicate circular 'wounds' were generated in confluent 4T1 cell monolayers. Residual fractional 'wound' areas were measured at 2, 4, 6, 8, and 24 h. Pictures were taken with an Olympus BX60 microscope and digital camera. The area of the wound was calculated using Scion Image software 1.62c (National Institute of Health, Bethesda, MD) for each time point.
Statistical analyses
Statistical analyses were performed using Microsoft Excel software using analysis of variance (ANOVA) for comparison of data among 4T1 cells or 4T1 cells expressing wild-type or mutant forms of EphA2 receptor; or unpaired Student's t-tests for comparison of data from control 4T1 cells with 4T1 cells expressing DC or W42 EphA2 mutants. All tests of significance were two sided, and differences were considered statistically significant when P-valueo0.05. All data were expressed as means7s.e.m.
